Vivakor Strengthens Executive Leadership Team

How will the new COO and CFO appointments affect Vivakor's operational efficiency and profitability? What immediate impact might these leadership changes have on VIVK's stock price and trading volume? How does the strengthening of Vivakor's executive team compare to recent leadership moves at peer companies in the biotech sector? Will the enhanced financial capabilities lead to new capital raising activities or strategic partnerships? What are the potential long‑term implications for Vivakor's growth trajectory and market positioning? Could the leadership changes influence analyst coverage or earnings guidance revisions? How might the market perceive the risk profile of Vivakor after these appointments? Are there any upcoming milestones or catalysts that could be accelerated by the new executive team?